Oktober 11, 2026

Keytruda

Moderna Stock 2026: Phase 3 Cancer Vaccine Wins — Is the MRNA Rally Already Too Far?

Moderna’s Phase 3 melanoma trial with Merck met its primary and key secondary endpoints. MRNA now has real oncology proof, but Q2 revenue was only $0.1B and cash burn remains.

Mehr lesen

Moderna’s Cancer Vaccine Breakthrough Is Real. The Valuation Is Now the Harder Question.

Moderna’s personalized cancer vaccine just delivered the kind of Phase 3 result the mRNA platform needed. The science looks far more credible today. The stock price, however, now asks a.

Mehr lesen